Physician profile
Samuel Parmar
NPI 1306188644
$16,777.67
in general payments reported to CMS, 2019-2025
24 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,804 · 2020: $216 · 2021: $11K · 2022: $1,716 · 2023: $431 · 2024: $58.79 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes USA Products LLC | $9,770.86 | 2021 | |
| Osteomed LLC | $1,302.07 | 2019 | |
| Stryker Corporation | $979.44 | 2021-2025 | Citrefix, Phalinx, Augment Injectable |
| Paragon 28, INC. | $973.28 | 2019-2022 | |
| Smith+Nephew, INC. | $856.24 | 2019-2025 | Collagenase Santyl, Allevyn Heel 10.5cm X 13.5cm Ctn 5, Iodosorb Ointment 40g USA |
| Microaire Surgical Instruments LLC | $800.00 | 2021 | |
| Bioventus LLC | $282.31 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Integra Lifesciences Corporation | $276.01 | 2019-2020 | |
| Wright Medical Technology, INC. | $261.89 | 2019-2020 | |
| Royal Biologics, INC. | $145.41 | 2019 | |
| Ets Wound Care LLC | $128.43 | 2023 | |
| Allergan, INC. | $125.00 | 2019 | |
| Depuy Synthes Sales INC. | $123.06 | 2019 | |
| Kci USA, INC. | $121.43 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.03 | 2025 | Jublia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Derma Sciences, INC. | $102.31 | 2019 | |
| Baxter Healthcare | $87.74 | 2019 | |
| Nevro Corp. | $87.13 | 2022 | |
| Celularity INC. | $77.00 | 2019 | |
| Organogenesis INC. | $41.99 | 2022 | |
| Medical Device Business Services, INC. | $36.84 | 2021 | |
| Zimmer Biomet Holdings, INC. | $34.18 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.35 | 2025 | Opsumit |
| Biocomposites INC | $18.67 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.